OptiBiotix Health – license agreement to incorporate a branded Tata Chemicals ingredient in India, STRONG BUY - target 78p
By Tom Winnifrith & Steve Moore | Tuesday 24 October 2023
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
OptiBiotix Health (OPTI) has announced a license agreement to incorporate Tata Chemicals’ proprietary short chain fructo-oligosaccharide Fossenceinto its SlimBiome and LeanBiome for the Indian market.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.